Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 1
2018 1
2019 1
2020 8
2021 4
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Trial watch: intratumoral immunotherapy.
Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Humeau J, et al. Among authors: le naour j. Oncoimmunology. 2021 Oct 15;10(1):1984677. doi: 10.1080/2162402X.2021.1984677. eCollection 2021. Oncoimmunology. 2021. PMID: 34676147 Free PMC article. Review.
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.
Le Naour J, Montégut L, Pan Y, Scuderi SA, Cordier P, Joseph A, Sauvat A, Iebba V, Paillet J, Ferrere G, Brechard L, Mulot C, Dubourg G, Zitvogel L, Pol JG, Vacchelli E, Puig PL, Kroemer G. Le Naour J, et al. Oncoimmunology. 2023 Jul 21;12(1):2237354. doi: 10.1080/2162402X.2023.2237354. eCollection 2023. Oncoimmunology. 2023. PMID: 37492227 Free PMC article.
Trial watch: IDO inhibitors in cancer therapy.
Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Le Naour J, et al. Oncoimmunology. 2020 Jun 14;9(1):1777625. doi: 10.1080/2162402X.2020.1777625. Oncoimmunology. 2020. PMID: 32934882 Free PMC article. Review.
Trial watch: TLR3 agonists in cancer therapy.
Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Le Naour J, et al. Oncoimmunology. 2020 Jun 2;9(1):1771143. doi: 10.1080/2162402X.2020.1771143. Oncoimmunology. 2020. PMID: 32934877 Free PMC article. Review.
Trial watch: STING agonists in cancer therapy.
Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Le Naour J, et al. Oncoimmunology. 2020 Jun 16;9(1):1777624. doi: 10.1080/2162402X.2020.1777624. Oncoimmunology. 2020. PMID: 32934881 Free PMC article. Review.
A Chemically Defined TLR3 Agonist with Anticancer Activity.
Le Naour J, Thierry S, Scuderi SA, Boucard-Jourdin M, Liu P, Bonnin M, Pan Y, Perret C, Zhao L, Mao M, Renoux C, Pérez-Lanzón M, Martin B, Kepp O, Kroemer G, Werlé B. Le Naour J, et al. Oncoimmunology. 2023 Jun 27;12(1):2227510. doi: 10.1080/2162402X.2023.2227510. eCollection 2023. Oncoimmunology. 2023. PMID: 37389102 Free PMC article.
The ambiguous role of FPR1 in immunity and inflammation.
Vacchelli E, Le Naour J, Kroemer G. Vacchelli E, et al. Among authors: le naour j. Oncoimmunology. 2020 Apr 30;9(1):1760061. doi: 10.1080/2162402X.2020.1760061. eCollection 2020. Oncoimmunology. 2020. PMID: 32391192 Free PMC article. No abstract available.
Local anesthetics elicit immune-dependent anticancer effects.
Bezu L, Wu Chuang A, Sauvat A, Humeau J, Xie W, Cerrato G, Liu P, Zhao L, Zhang S, Le Naour J, Pol J, van Endert P, Kepp O, Barlesi F, Kroemer G. Bezu L, et al. Among authors: le naour j. J Immunother Cancer. 2022 Apr;10(4):e004151. doi: 10.1136/jitc-2021-004151. J Immunother Cancer. 2022. PMID: 35483744 Free PMC article.
26 results